Navigation Links
Nexavar Data to be Presented at 46th American Society of Clinical Oncology Annual Meeting
Date:5/20/2010

ination with Capecitabine in Patients with Advanced Breast Cancer.
  • Patricia Gomez, M.D., Breast Cancer Center, Vall d'Hebron University Hospital, Barcelona, Spain
  • Abstract 1083, General Poster Session, Breast Cancer Track
  • Saturday, June 5, 2010, 2:00-6:00 p.m., S Hall A2

"With more than 70 investigator and company sponsored studies being presented at ASCO, we look forward to continuing our work with investigators to understand how Nexavar may fit into other areas of the therapeutic landscape, particularly with respect to how biomarkers status may guide selection of therapy, which is a step toward personalized medicine," said Ted W. Love, M.D., Executive Vice President and Head of Research and Development at Onyx Pharmaceuticals.  

Nexavar's Differentiated Mechanism

Nexavar, an oral anti-cancer therapy, is currently approved in more than 90 countries for liver cancer where it remains the only approved systemic agent proven to extend survival and in more than 95 countries for the treatment of patients with advanced kidney cancer.  Nexavar inhibits processes involved in both the tumor cell and tumor vasculature.  In preclinical studies, Nexavar has been shown to inhibit members of two classes of kinases thought to be involved in both cell proliferation (growth) and angiogenesis (blood supply) – two important processes that enable cancer growth.  These kinases included Raf kinase, VEGFR-1, VEGFR-2, VEGFR-3, PDGFRB, KIT, FLT-3 and RET.  

Nexavar is also being evaluated by other companies, international study groups, government agencies a
'/>"/>

SOURCE Bayer HealthCare Pharmaceuticals, Inc.; Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Onyx Pharmaceuticals Announces a Teleconference and Webcast to Provide an Update on Nexavar and Report Full Year 2007 Financial Results
2. Bayer and Onyx Announce Nexavar Data Presentations at 44th American Society of Clinical Oncology Annual Meeting
3. Onyx Pharmaceuticals Announces a Teleconference and Webcast to Provide an Update on Nexavar
4. Bayer and Onyx Announce Nexavar Data Presentations at 45th American Society of Clinical Oncology Annual Meeting
5. Three Studies by Independent Scientists Highlighting Pressure Cycling Technology (PCT) to be Presented this Week at the British Mass Spectrometry Societys 29th Annual Meeting
6. Survival Data Presented From Phase II Study of Investigational Drug ZD4054 in Hormone-Resistant Prostate Cancer Patients
7. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
8. Results of Colon Cancer Study Utilizing Pressure Cycling Technology (PCT) Presented at the American College of Gastroenterology Annual Scientific Meeting
9. Kuvan, Naglazyme and Aldurazyme Data to Be Presented at the 57th Annual Meeting of the American Society of Human Genetics
10. Micromet Data Presented at the International AACR-NCI-EORTC Conference Support the Development of Adecatumumab (MT201) in Earlier Stage Cancer Disease Settings
11. Three PDX (Pralatrexate) Studies Presented at the 2007 AACR-NCI-EORTC Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... and NEW YORK , ... (OTCQB: ACCPD), formerly Access Pharmaceuticals, Inc. (ACCP), a ... announced it has implemented a 1-for-50 reverse split ... of trading on Friday, October 24, 2014. PlasmaTech,s ... under new CUSIP number 72754H109 and temporary ticker ...
(Date:10/25/2014)... , October 24, 2014 ... http://www.researchandmarkets.com/research/t5t5pd/the_global_market ) has announced the addition of ... Graphene And Other 2-D Nanomaterials "  report ... http://photos.prnewswire.com/prnh/20130307/600769) , ,CNTs and graphene are the ... to man, with a performance-per-weight greater than ...
(Date:10/22/2014)... 21, 2014 The Americas Inorganic ... refrigerants market in Americas with analysis and forecast ... the Americas Inorganic Refrigerants Market report, to get ... also provides a glimpse of the segmentation in ... by various tables and figures. , ...
(Date:10/22/2014)... WriteResult, LLC – a premier ... working with a team of researchers from Yale University’s ... Farming Collaborative to provide electronic questionnaire data collection through ... which started in May, aims to evaluate the impact ... exposure to and participation in urban agriculture to impact ...
Breaking Biology Technology:PlasmaTech Biopharmaceuticals, Inc. Announces Reverse Stock Split, Ticker Change and Launches New Corporate Website 2The Global Market for Carbon Nanotubes, Graphene and Other 2-D Nanomaterials 2The Global Market for Carbon Nanotubes, Graphene and Other 2-D Nanomaterials 3The Global Market for Carbon Nanotubes, Graphene and Other 2-D Nanomaterials 4The Americas Inorganic Refrigerants Market is estimated to grow to $71.6 million by 2018 - New Report by MicroMarket Monitor 2The Americas Inorganic Refrigerants Market is estimated to grow to $71.6 million by 2018 - New Report by MicroMarket Monitor 3myPROpad™ Topic of Panel Discussion at the Yale Food Systems Symposium 2myPROpad™ Topic of Panel Discussion at the Yale Food Systems Symposium 3
... international scientific ... ... of antibody fragment therapeutics, today announced that it has,achieved high concentrations ... delivery via eye drops. These data were confirmed in,several independent preclinical ...
... from sunlight falling on only 9 percent of ... United States electricity needs if the energy could ... current-generation solar cell technologies are too expensive and ... of Northwestern University researchers has developed a new ...
... Monday, February 25, 2008 at ... ... Biopharmaceuticals,Inc. (Nasdaq: KERX ), a biopharmaceutical company focused on the,acquisition, ... of life-threatening,diseases, including diabetes and cancer (the "Company"), today announced,its results ...
Cached Biology Technology:ESBATech's Antibody Fragments Demonstrate Penetration into the Eye with Topical Delivery via Eye Drops 2ESBATech's Antibody Fragments Demonstrate Penetration into the Eye with Topical Delivery via Eye Drops 3Special coating greatly improves solar cell performance 2Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2007 Financial Results 2Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2007 Financial Results 3Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2007 Financial Results 4Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2007 Financial Results 5Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2007 Financial Results 6
(Date:10/22/2014)... Northwestern Medicine® scientists helps explain how bipolar disorder affects ... drug therapies to treat the mental illness. , ... same method recognized with the 2014 Nobel Prize ... tissue from mice with bipolar-like behaviors. In the synapses ... "nanodomain" structures with concentrated levels of ANK3 -- the ...
(Date:10/18/2014)... 2014 Psychological stress and stress-related psychiatric disorders are ... but the molecular mechanisms underlying this relation ... to the development of targeted preventive strategies ... devastating diseases. This work is presented at ... Berlin., Now an international group of researchers ...
(Date:10/17/2014)... University of Copenhagen have shown for the first time ... Cystic fibrosis patients, giving them the opportunity to get ... infections. , The study also discovered the bacterial growth ... was halted or slowed down by the immune cells. ... oxygen and helped "suffocate" the bacteria, forcing the bacteria ...
Breaking Biology News(10 mins):Bipolar disorder discovery at the nano level 2Researchers find why depression and aging linked to increased disease risk 2Scientists opens black box on bacterial growth in cystic fibrosis lung infection 2
... a corporation has a public relations crisis, the news media ... to new research in the Journal of Consumer Research the ... and the situation. "A company can control what face ... the face shape of this person is not a trivial ...
... better at making product choices, according to a new ... who understand their emotional ability can make higher quality ... explain the authors, Blair Kidwell, David M. Hardesty, and ... know a lot about nutrition and know what foods ...
... PROVIDENCE, R.I. [Brown University] Imagine being paralyzed, unable to ... to five million Americans suffer from this debilitating situation. Or ... millions of Americans are affected by these infirmities. Now ... your hands or arms enough to tap out an e-mail ...
Cached Biology News:Brown to host conference on advances in neurotechnology 2Brown to host conference on advances in neurotechnology 3
... The T2-04 is an ultra-compact pump available ... (T2-04 TH) and ideal for use in portable ... 7 slpm, this pump works well in environments ... weight, and compact size are critical., Offers ...
XA7 B6...
Curcumin is an extract of turmeric root with antioxidant, anti-tumor promoter, and anti-inflammatory properties. Curcumin inhibits the induction of NOS in macrophages....
... The MEGAscript RNAi Kit ... of large mass amounts of ... in non-mammalian systems. The MEGAscript ... Ambions patented high-yield transcription technol-ogy ...
Biology Products: